Table 2. Treatment characteristics.
| Variable | No (%) |
|---|---|
| Primary tumor resected (n=546) | |
| Yes | 466 (85.3) |
| No | 80 (14.7) |
| Nephrectomy (n=546) | |
| Total | 439 (80.4) |
| Partial | 27 (4.9) |
| No | 80 (14.7) |
| Previous radiation therapy (n=532) | |
| No | 380 (71.4) |
| Yes | 152 (28.6) |
| Line of Temsirolimus therapy (n=544) | |
| First line | 242 (44.5) |
| Second line | 144 (26.5) |
| Third or later line | 158 (29.0) |
| Systemic pretreatment (n=299) | |
| Cytokines | 75 (25.1) |
| Sunitinib | 139 (46.5) |
| Sorafenib | 34 (11.4) |
| Axitinib | 1 (0.3) |
| Bevacizumab | 20 (6.7) |
| Temsirolimus | 2 (0.7) |
| Everolimus | 1 (0.3) |
| Others | 15 (5.0) |
| Missing | 12 (4.0) |
| Median duration of treatment with Temsirolimus (months, IQR) | 3.3 (1.5–7.9) |
| Range | 0–49.1 |
| Median dose intensity (IQR) | 89.9% (77.2–100) |
| Discontinued temsirolimus | 424 (77.5) |
| Response evaluation (n=385) | |
| Complete remission (CR) | 2 (0.5) |
| Partial remission (PR) | 53 (13.8) |
| Stable disease (SD) | 194 (50.4) |
| Progressive disease (PD) | 136 (35.3) |
No, number; IQR, inter-quartile range; CR, complete remission; PR, partial remission; SD, stable disease; PD, progressive disease.